BIO Will Have New President By End Of Year; Feldbaum Stepping Down
This article was originally published in The Pink Sheet Daily
Executive Summary
BIO President Carl Feldbaum is stepping down after 11 years. His successor will face emerging debate on "generic" biologics and implementation of the Medicare law.
You may also be interested in...
BIO’s New CEO, Michelle McMurry-Heath, Aims To ‘Change The Dialogue’ Around Science
Former senior leader in J&J’s medical devices business will take over the reins from Jim Greenwood in June; an immunologist by training, McMurry-Heath brings a resume that is long on scientific, regulatory and corporate experience, but she also has some political qualifications under her belt.
BIO’s New CEO, Michelle McMurry-Heath, Aims To ‘Change The Dialogue’ Around Science
Former senior leader in J&J’s medical devices business will take over the reins from Jim Greenwood in June; an immunologist by training, McMurry-Heath brings a resume that is long on scientific, regulatory and corporate experience, but she also has some political qualifications under her belt.
BIO Top Job May Go To Rep. Greenwood
Oversight Subcommittee chairman confirms he is considering leaving Congress to pursue a new opportunity, but says he will have no further comment until he makes a decision "in the very near future." Greenwood has been among most active legislators on pharmaceutical issues, and has worked with BIO on stem cell and human subject protection proposals.